Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0948265 (metabolic syndrome)
 24,271 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A number of factors used to define the metabolic syndrome (MS) differ between African-American and European-American patients, which raises the question whether the individual constellation of MS components would impact cardiovascular risk. Our objectives were to assess the association between the MS and coronary artery disease (CAD) across ethnicities and to explore whether the constellation used to define the syndrome would impact any such association. We studied the distribution of the MS and its relation to CAD in 304 European-American subjects and 224 African-American subjects undergoing diagnostic coronary angiography. The overall prevalence of the MS in European-American and African-American subjects were 65.5% and 49.1%, respectively. Compared with European-American subjects, the lipid components of the syndrome were less frequent among African-American subjects (44% vs 64% [p <0.001] for high-density lipoprotein [HDL] cholesterol and 21% vs 51% [p <0.001] for triglyceride, respectively). The prevalence of CAD was significantly higher in subjects with MS across ethnicity (71.1% of European-American subjects and 56.6% of African-American subjects, p = 0.017 and p = 0.046, respectively). Multiple regression analyses demonstrated an association of blood pressure and HDL cholesterol with CAD among European-American subjects, which remained significant taking other risk factors into account (r(2) = 0.542, p <0.001). In conclusion, presence of CAD was more common among subjects with MS independently of ethnicity. Of the MS components, blood pressure was associated with CAD among European-American subjects. Although our findings may not be directly extrapolated to the population at large, they illustrate the importance of a high-risk metabolic environment as a cardiovascular risk factor.
 ...
PMID:Metabolic syndrome components in african-americans and European-american patients and its relation to coronary artery disease. 1771 28

Adiponectin is known to play a role in fatty acid and glucose metabolism through a change in insulin sensitivity and activation of fuel oxidation by AMP-activated protein kinase. Adiponectin can be considered an important factor able to modulate the adipovascular axis which, through genomic and environmental influences, affects the cardiovascular risk milieu, from the pre-metabolic syndrome-- through the metabolic syndrome--to the overt atherosclerotic process and its clinical manifestations. Hypoadiponectinaemia can be viewed as an early sign of a complex cardiovascular risk factor predisposing to the atherosclerosis process as well as a contributing factor accelerating the progress of the atherosclerotic plaque. In addition, adiponectin per se holds a protective role thanks to its anti-inflammatory and antiatherogenic properties. The early identification of patients "at cardiovascular risk" means in the current practice to search for indexes of metabolic derangements and pro-inflammatory status (adiponectin) from adolescence and childhood.
 ...
PMID:Adiponectin and the cardiovascular system: from risk to disease. 1790 7

We examined the association of dietary carbohydrates, protein, fat (including fatty acid subtypes) and alcohol with the metabolic syndrome and its components, in a cross-sectional study of 1626 patients with at least one cardiovascular risk factor. Multivariate nutrient density substitution models were used to examine the associations between macronutrients (assessed by 24 h dietary recall) and the metabolic syndrome. These models express the effects of 'substituting' one macronutrient for another without altering total energy intake. Increases in carbohydrates offset by isoenergetic decreases in either fat or protein were associated with a decrease in the prevalence of the metabolic syndrome (OR 0.87 (95 % CI 0.81, 0.93), P 0.10). Consumption of up to one standard alcoholic drink per d was associated with a lower prevalence of the metabolic syndrome when compared with non-drinkers (OR 0.67 (95 % CI 0.50, 0.89), P = 0.006); however, these benefits were weakened with higher levels of alcohol intake (P = 0.10 for one to three drinks and P = 0.29 for >three drinks). Thus, a diet high in carbohydrates, low in fat and protein, with low-to-moderate alcohol intake, is associated with a reduced prevalence of the metabolic syndrome.
 ...
PMID:The association between dietary macronutrient intake and the prevalence of the metabolic syndrome. 1819 90

There is strong epidemiological evidence that HDL-cholesterol (HDL-C) is an independent cardiovascular risk factor. A low HDL-C is a common finding in the general population, and is a feature of metabolic syndrome, the prevalence of which is increasing globally. The importance of HDL-C as a coronary risk factor is generally accepted, and has been incorporated into most of the commonly applied risk engines. There are several causes of a low HDL-C, including rare genetic abnormalities, and more common conditions associated with lifestyle and drug therapy. Not all of these are associated with an increased risk of coronary disease. A better understanding of HDL metabolism and the mechanisms by which it may exert its protective effects has revealed why this may be the case. New therapeutic targets have also been identified that may allow HDL-C to be raised in patients with low levels. However, good clinical endpoint studies are still required to enable the setting of absolute target values for HDL-C in patients at high cardiovascular risk.
 ...
PMID:HDL-cholesterol modulation and its impact on the management of cardiovascular risk. 1832 73

The metabolic syndrome represents a cluster of cardiovascular risk factors that occur together more commonly than expected from the prevalence of their individual rates. Insulin resistance is widely believed to be the common denominator causing, in susceptible individuals, the development of various cardiovascular risk factor components of the syndrome (e.g., hyperlipidemia, hypertension, and hyperglycemia). The major cause of this insulin resistance appears to be obesity, especially the accumulation of visceral fat. This obesity is due to the combination of excessive caloric intake and inadequate physical activity rather than alterations in energy utilization. In individuals whose beta cells cannot increase their insulin secretion adequately to compensate for insulin resistance, hyperglycemia occurs.
 ...
PMID:Glycemic control in the metabolic syndrome and implications in preventing cardiovascular disease. 1837 Jul 49

The metabolic syndrome increases the risk of atherothrombotic cardiovascular disease (CVD) and diabetes. In turn, diabetes promotes the development of atheroma and is regarded as a coronary heart disease risk equivalent. A multifactorial therapeutic strategy is advocated for patients with the metabolic syndrome to improve cardiovascular risk factor profiles and to reduce the chances of developing type 2 diabetes. Individual components of the syndrome must be addressed using safe, efficacious, and cost-effective measures. There is general agreement that lifestyle modifications, including control of body weight, avoidance of central adiposity, adoption of an antiatherogenic diet, and regular physical activity, are crucial. However, as the magnitude of the individual components of the metabolic syndrome increases with time, lifestyle measures are often insufficient. An individual with metabolic syndrome will often require drug treatment for hyperglycemia, atherogenic dyslipidemia, and high blood pressure, together with antiplatelet therapy. Reducing the need for polypharmacy is an increasingly important consideration for clinicians and the pharmaceutical industry; to date, no single therapy has emerged that targets the root cause(s) of the syndrome. HMG-CoA reductase inhibitors are important agents that reduce CVD morbidity and mortality, in people with impaired fasting glucose or metabolic syndrome. Selective cannabinoid receptor antagonists appear promising because they improve or attenuate several key defects of the syndrome. Thiazolidinediones and metformin are presently licensed for treatment of type 2 diabetes but may prove to have a broader role in future. Novel insulin-sensitizing drugs are under investigation. Drugs that act to prevent or reverse endothelial dysfunction may be of particular utility in preventing cardiovascular disease, especially if initiated before tissue damage has become irreversible. Insulin therapy, which has antiinflammatory and endothelial protective properties, has been shown to reduce morbidity and mortality in high-risk nondiabetic patients during critical illness. Potential synergy between different classes of drugs with metabolic and/or cardiovascular protective properties merits further investigation.
 ...
PMID:Prevention of cardiovascular complications of the metabolic syndrome: focus on pharmacotherapy. 1837 Jul 50

Choline is involved in the synthesis of phospholipids, including blood lipids, and is the immediate precursor of betaine, which serves as a methyl group donor in a reaction converting homocysteine to methionine. Several cardiovascular risk factors are associated with plasma homocysteine, whereas little is known about their relationship to choline and betaine. We examined the relation of plasma choline and betaine to smoking, physical activity, BMI, percent body fat, waist circumference, blood pressure, serum lipids, and glucose in a population-based study of 7074 men and women aged 47-49 and 71-74 y. Overall plasma concentrations (means +/- SD) were 9.9 +/- 2.3 micromol/L for choline and 39.5 +/- 12.5 micromol/L for betaine. Choline and betaine were lower in women than in men and in younger subjects compared with older (P < 0.0001). Multivariate analyses showed that choline was positively associated with serum triglycerides, glucose, BMI, percent body fat, waist circumference (P < 0.0001 for all), and physical activity (P < 0.05) and inversely related to HDL cholesterol (P < 0.05) and smoking (P < 0.0001). Betaine was inversely associated with serum non-HDL cholesterol, triglycerides, BMI, percent body fat, waist circumference, systolic and diastolic blood pressure (P < 0.0001 for all), and smoking (P < 0.05) and positively associated with HDL cholesterol (P < 0.01) and physical activity (P < 0.0001). Thus, an unfavorable cardiovascular risk factor profile was associated with high choline and low betaine concentrations. Choline and betaine were associated in opposite directions with key components of metabolic syndrome, suggesting a disruption of mitochondrial choline dehydrogenase pathway.
 ...
PMID:Divergent associations of plasma choline and betaine with components of metabolic syndrome in middle age and elderly men and women. 1842 1

The natriuretic peptide system includes three known peptides: atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), and C-type natriuretic peptide (CNP). They contribute to the regulation of cardiovascular homeostasis through diuretic, natriuretic, and vasodilatory properties. Among them, ANP has received particular attention because of its effects on blood pressure regulation and cardiac function. Although the potential for its therapeutic application in the treatment of hypertension and heart failure has been evaluated in several experimental and clinical investigations, no pharmacological approach directly targeted at modulation of ANP levels has ever reached the stage of being incorporated into clinical practice. Recently, ANP has also received attention as being a possible cardiovascular risk factor, particularly in the context of hypertension, stroke, obesity, and metabolic syndrome. Abnormalities in either peptide levels or peptide structure are thought to underlie its implied role in mediating cardiovascular diseases. Meanwhile, BNP has emerged as a relevant marker of left ventricular (LV) dysfunction and as a useful predictor of future outcome in patients with heart failure. This review deals with the major relevant findings related to the cardiovascular and metabolic effects of natriuretic peptides, to their potential therapeutic use, and to their role in mediating cardiovascular diseases.
 ...
PMID:Natriuretic peptides: an update on bioactivity, potential therapeutic use, and implication in cardiovascular diseases. 1846 48

The Japan Atherosclerosis Society (JAS) guidelines for the prevention of atherosclerotic diseases, proposing management for LDL cholesterol as the primary target, have successfully contributed to the prevention of cardiovascular events; however, recently, the impact of hypertriglyceridemia as an additional cardiovascular risk has become understood, especially in light of the rise in obesity, metabolic syndrome, and diabetes in the Japanese population. Rather than waiting to obtain conclusive domestic data confirming that hypertriglyceridemia is a cardiovascular risk factor and that its management is efficacious, we propose guidelines for hypertriglyceridemia using non-HDL cholesterol as a second target.
 ...
PMID:Proposed guidelines for hypertriglyceridemia in Japan with non-HDL cholesterol as the second target. 1860 17

Cardiovascular disease is unanimously recognized as the major burden in type 2 diabetes, in terms of both mortality and morbidity. There is an extensive evidence coming from epidemiological studies that supports this statement. The presence of the metabolic syndrome confers a higher risk of long-term death, and dysglycemia appears to be responsible for the most of the excess risk. The metabolic syndrome also has an essential role in the modern concept of cardiovascular prevention.Global cardiovascular risk represents the action and consequences of all risk factors that simultaneously or sequentially act on the body, leading to atherogenesis/atherosclerosis. In daily practice, a stepwise approach to control cardiovascular risk in people with type 2 diabetes has been proposed. This algorithm comprises three steps: identification of cardiovascular risk factors, interpretation of global cardiovascular risk, and intervention for all identified risk factors and diseases. In the past decades, the whole concept of diabetes and the metabolic syndrome care has undergone a radical change. From here the concept of modern management of those diseases emerged: early, multi-factorial and intensive control. This concept emphasized early and aggressive interventions for all cardiovascular risk factors in the long-term management. The model of multiple cardiovascular risk factor intervention ought to be implemented in daily practice as much as possible. This offers a unique opportunity to reduce the devastating cardiovascular morbidity and mortality in people with type 2 diabetes and the metabolic syndrome.
 ...
PMID:Practical aspects of the control of cardiovascular risk in type 2 diabetes mellitus and the metabolic syndrome. 1865 Sep 87


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>